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Abstract
Background: Benefits of beta-adrenergic receptor blockers (BB) fo-
llowing ST-elevation myocardial infarction (STEMI) are based on data 
before primary percutaneous coronary intervention (PCI) became the 
therapeutic first choice. This study examined the relationship between 
BB dose and magnitude of left ventricular ejection fraction (LVEF) 
improvement in STEMI following primary PCI.
Methods and Findings: A total of 235 STEMI patients following 
primary PCI who underwent echocardiography during the acute pha-
se and over 6 months from onset were studied retrospectively. Serial 
LVEFs were assessed for three groups: no BB (n=33), carvedilol (n=163), 
and bisoprolol (n=42). Left ventricular reverse remodeling (RR) was 
defined as LVEF improvement ≥10%. All patients received fixed doses 
of BB and renin-angiotensin system inhibitor during observation. The 
median interval between echocardiographs was 526 days. The mean 
LVEF change was +2.6% (acute: 53.9±9.9%, chronic: 56.4±10.6%). 
Carvedilol and bisoprolol groups showed LVEF improvement, but none 
was seen in the no BB group (+3.7±6.5%, +3.8±6.9%, -4.2±5.0%, 
P<0.0001, respectively). The LVEF improvement effect was BB dose 
dependent. Therapy with BBs had a high rate of RR (no BB 0%, car-
vedilol 19.4%, bisoprolol 16.7%, P=0.0225, respectively). Multivariate 
analysis showed the following predictors of RR: baseline LVEF <50% 
and regular dose of BB, ≥10 mg of carvedilol or ≥1.25 mg of bisoprolol 
(Odds ratio 2.35, 95% Confidence Interval [CI] 1.12-5.02, P=0.0242; 
Odds ratio 4.45, 95% CI 2.06-10.27, P=0.0001).
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Introduction
Various large clinical trials confirmed that renin-
angiotensin system inhibitors or beta-adrenergic 
blockers (BB) have a preventive effect in left ven-
tricular remodeling and improvement in long-term 
survival. [1-8] Left ventricular reverse remodeling 
(RR) produced by these optimal medical therapy 
was recognized as an important surrogate marker 
toward improvement of clinical outcomes. Current 
practice guidelines on the management of ST-ele-
vation myocardial infarction (STEMI) recommends 
immediate BB introduction during hospitalization. 
[9, 10] However, these guidelines are mainly based 
on data before primary percutaneous coronary in-
tervention (PCI) became the first choice for revas-
cularization.
Recent studies, such as the OACIS trial and post-
hoc sub-analysis of the J-Cypher registry, proved 
that BB did not always contribute to the impro-
vement of long-term outcomes in STEMI. [9, 11] 
The beneficial effects seen in those studies were 
limited in patients with higher risk or low left ven-
tricular ejection fraction (LVEF). These studies su-
ggested potential room for revision regarding BB 
dose or indication for STEMI in the current era, 
when prompt revascularization by primary PCI is a 
standard therapy.
In this study, serial echocardiographic LVEF data 
at acute and chronic phase were analyzed to study 
the relationship between the dosage of BB and the 
magnitude of LVEF improvement in STEMI following 
standard primary PCI.
Methods
Study design and population.
To study the relationship between the dosage of BB 
and the magnitude of LVEF improvement in STEMI 
following primary PCI, this study surveyed STEMI 
patients who underwent primary PCI during January 
2006 and March 2015 retrospectively at Tokai Uni-
versity School of Medicine. The BB dose at hospital 
discharge was assessed for discussion regarding the 
dosing-improvement relationship.
Inclusion criteria included those patients who 
were administrated BB during hospitalization and 
continued on a fixed dose of BB their echocardio-
graphic LVEF evaluation at the acute phase to the 
chronic phase. A total of 235 patients were inclu-
ded in the study population and divided into three 
groups by type of BB administered: no BB (n=33), 
carvedilol (n=163), or bisoprolol (n=42). To determi-
ne the change in LVEF from acute phase to chronic 
phase, LVEF was evaluated by echocardiography 
within 3 months from STEMI onset (defined as the 
acute phase) and at more than 6 months from STE-
MI onset with more than a 5-month interval from 
acute phase echocardiography (defined as the chro-
nic phase) (Figure 1). 
Keywords
ST-Elevation Myocardial Infarction; Beta-Adrenergic Blockers; Reverse 
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Conclusions: Immediate BB administration following primary PCI for 
STEMI provided a dose-dependent LVEF improvement. A LVEF <50% 
and regular dose of BB are predictors of RR.
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Exclusion criteria were as follows: STEMI patients 
who did not undergo primary PCI, those whose BB 
dose changed during the observation period, those 
who did not receive renin-angiotensin system in-
hibitor during observation period, those who had 
been administrated BB before STEMI onset, those 
without acute phase echocardiographic evaluation 
within 3 months from STEMI onset, those without 
chronic phase echocardiographic evaluation per-
formed more than 5 months from the acute pha-
se echocardiographic evaluation and more than 6 
months from STEMI onset, those with new onset 
of myocardial infarction or any cardiac surgery (in-
cluding coronary artery bypass grafting) after STE-
MI and during the observation period, and those 
patients who were treated with a BB other than 
carvedilol or bisoprolol.
All patients gave written informed consent; this 
study was designed in accordance with the ethical 
standards of the General Clinical Research Center of 
Tokai University School of Medicine. This study ob-
tained all required approvals by the Tokai University 
institutional review board.
Medications.
The timing of introduction, dose, or selection of 
proper medications including BB during hospitaliza-
tion was determined by an experienced cardiologist 
team with consideration of patients’ general status. 
All study patients received fixed doses of BB and 
renin-angiotensin system inhibitor, angiotensin-con-
verting enzyme inhibitor, or angiotensin II receptor 
blockers during the observation period. 
Serial echocardiographic evaluations.
All echocardiographic studies were performed by 
an experienced investigator with the patient in the 
supine position, using the Xario XG with a 1.8-4.2-
MHz PST-25AT transducer (Toshiba Medical Systems 
Corporation; Tochigi, Japan). The recorded echocar-
diographic data were evaluated and assessed based 
on the recommendations of the American Socie-
ty of Echocardiography. [12] To assess the impro-
vement of LVEF and RR effect by BB, serial LVEFs 
were evaluated by 2-dimensional echocardiography 
at the acute and chronic phases with a more than 
5-month interval between evaluations. Acute pha-
se evaluation was performed under stable hemo-
dynamic status within 3 months after STEMI onset. 
Chronic phase evaluation was performed at least 
6 months from STEMI onset (Figure 1). For 2-di-
mensional measurements, the LVEF was calculated 
in apical 4-chamber and apical 2-chamber views 
at end-diastole and at end-systole by modified 
Simpson’s rule. [12, 13] Serial LVEFs at acute and 
chronic phases were evaluated using the same clea-
rest angle. Papillary muscles were excluded from the 
cavity in the tracking. End-diastole was defined at 
the onset of the QRS wave on electrocardiographic 
(ECG) monitoring, and end-systole was defined as 
the time of the frame preceding mitral valve ope-
ning.
In M-mode recording, the septal wall thickness, 
posterior wall thickness, and left ventricular internal 
dimensions were measured over several cardiac cy-
cles in the parasternal short-axis acoustic window 
to optimize medial-lateral beam orientation. These 
parameters were measured at the level of the mitral 
valve leaflet tips at the left ventricular minor axis. 
The thickness of the ventricular wall and chamber 
size were measured as the distance between the 
leading edge echoes.
Definitions
STEMI was defined as acute when the patient pre-
sented within 24 hours of symptom onset and ECG 
Figure 1:  Time line of echocardiographic eva-
luations.
InternatIonal archIves of MedIcIne 
sectIon: cardIology 
ISSN: 1755-7682
2016
Vol. 9 No. 115
doi: 10.3823/1986
This article is available at: www.intarchmed.com and www.medbrary.com 4
findings on arrival showed persistent ST-segment 
elevation >1 mm in two contiguous leads, with 
new or presumed new left bundle branch block. 
The final diagnosis was made by emergency coro-
nary angiography, and all patients were underwent 
primary PCI.
Improvement in LVEF was assessed from the di-
fference calculated by subtracting LVEF at chronic 
phase from the value determined in the acute pha-
se. RR was defined as LVEF improvement >10%. 
[14, 15] 
Statistical analysis
Numerical factors with normal distribution are 
shown as mean ± standard deviation. Numerical 
factors with skewed distribution are shown as 
medians (interquartile range). Student’s t-test was 
used to determine statistically significant differen-
ces in clinical parameters between two groups 
with normal distribution. The Wilcoxon rank-sum 
test was used to determine statistically significant 
differences in clinical values between two diffe-
rent groups with skewed distribution. Analysis of 
variance test was performed to compare numerical 
parameters among the three groups. Fisher's exact 
test was applied to determine the difference bet-
ween three categorical variables. The Steel-Dwass 
test was used to test for between-group differen-
ces in numerical factors with skewed distribution. 
The multiple logistic regression model for examine 
the parameters to achieve RR included variables 
with p <0.10 in the univariate analysis. The good-
ness of fit for multivariable analysis was tested by 
the Hosmer-Lemeshow test. P-values in the tables 
show the statistical comparison among the three 
groups. The results of multivariate analysis were 
summarized by odds ratios (OR) and 95% confi-
dence intervals (CI). A value of P <0.05 was con-
sidered statistically significant. All statistical calcu-
lations were performed using JMP version 11 (SAS 
Institute, Inc.; Cary, NC, USA).
Results
To study the relationship between dosage of BB 
and the magnitude of LVEF improvement in STEMI 
following primary PCI, our study examined the serial 
echocardiographic evaluations at acute and chronic 
phase. Baseline characteristics are shown in Table 
1. Among the total of 235 patients, the mean age 
Table 1.  Distribution of the domains and facets of QoL. João Pessoa, PB, 2015.
Overall 
(n=235)
No BB 
(n=33)
Carvedilol 
(n=160)
Bisoprolol 
(n=42)
P value
Age, years 63.3 ± 12.1 66.9 ± 13.7 62.4 ± 12.1 64.0 ± 10.8 0.1362
Male 192 (83.8%) 23 (69.7%) 137 (85.6%) 32 (76.2%) 0.0584
Height, cm 162.5 ± 8.3 160.0 ± 8.6 163.5 ± 7.9 161.0 ± 9.1 0.0292
Weight, kg 64.1 ± 13.0 58.5 ± 12.6 65.7 ± 12.8 62.3 ± 12.8 0.0084
Current smoking 90 (38.3%) 8 (24.2%) 70 (43.8%) 12 (28.6%) 0.0834
Diabetes mellitus 79 (33.6%) 14 (42.4%) 55 (34.4%) 10 (23.8%) 0.2233
Insulin 7 (3.0%) 2 (6.1%) 5 (3.1%) 0 0.3033
Dyslipidemia 173 (73.6%) 19 (57.6%) 126 (78.8%) 28 (66.7%) 0.0270
Hypertension 173 (73.6%) 25 (75.8%) 121 (75.6%) 27 (64.3%) 0.3178
Family history 31 (13.2%) 4 (12.1%) 22 (13.8%) 5 (11.9%) 0.9336
Prior PCI 22 (9.4%) 3 (9.1%) 13 (8.1%) 6 (14.3%) 0.4744
Prior CABG 1 (0.4%) 0 1 (0.6%) 0 0.7903
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Overall 
(n=235)
No BB 
(n=33)
Carvedilol 
(n=160)
Bisoprolol 
(n=42)
P value
Prior stroke 24 (10.2%) 3 (9.1%) 18 (11.3%) 3 (7.1%) 0.7172
Hemodialysis 2 (0.9%) 0 1 (0.6%) 1 (2.4%) 0.4618
Hemoglobin, mg/dL 14.4 ± 2.1 14.0 ± 2.0 14.7 ± 1.9 13.5 ± 2.4 0.0014
LDL cholesterol, mg/dL 125.4 ± 39.3 125.0 ± 43.8 125.3 ± 39.4 126.1 ± 36.0 0.9903
HDL cholesterol, mg/dL 50 (40-59) 50 (43-59) 49 (39-59) 53 (40.5-62.5) 0.1920
Triglyceride, mg/dL 100.5 (56-156) 126 (53.5-178) 100 (56-154) 93 (60-140.5) 0.4406
Serum creatinine, mg/dL 0.8 (0.7-1) 0.89 (0.755-1.17) 0.8 (0.7-0.99) 0.835 (0.6675-1) 0.4492
Estimated GFR, ml/min/1.73 m2 71.5 ± 22.4 65.9 ± 27.5 73.0 ± 20.8 70.0 ± 23.5 0.2298
BNP, pg/dL 45.4 (19.2-154.4) 43.2 (21.1-244.8) 54.1 (18.825-154.025) 40.85 (18.75-118) 0.6579
GRACE risk score 149.4 ± 36.2 155.4 ± 38.8 145.9 ± 34.6 157.7 ± 38.9 0.1000
Systolic BP on arrival, mmHg 135.4 ± 32.3 136.1± 30.2 137.5 ± 34.2 126.8 ± 24.7 0.1621
Diastolic BP in arrival, mmHg 77.0 ± 23.8 71.6 ± 23.9 79.2 ± 24.1 73.2 ± 21.7 0.1292
Shock on arrival 17 (7.2%) 4 (12.1%) 11 (6.9%) 2 (4.8%) 0.4521
Killip I 145 (61.7%) 19 (57.6%) 101 (63.1%) 25 (59.5%) 0.1547
De novo lesion 229 (97.5%) 32 (97.0%) 157 (98.1%) 40 (95.2%) 0.3535
Three vessel disease 11 (4.7%) 1 (3.0%) 8 (5.0%) 2 (4.8%) 0.9027
Peak CPK, IU/L 2497 (1348-4638) 2181 (874-3565.5) 2888 (1398.75-4688.5) 2136 (1242.75-4731.5) 0.8679
Length of hospitalization, day 10 (8-14) 8 (7-16) 10 (8-14) 11 (9-14) 0.0645
Medication at discharge
ACEI/ ARB 184 (78.3%)/51 (21.7%) 28 (84.9%)/5 (15.2%) 121 (75.6%)/39 (24.4%) 35 (83.3%)/7 (16.7%) 0.3443
Statin 210 (89.3%) 27 (81.8%) 144 (90.0%) 39 (92.9%) 0.2748
DAPT 220 (93.6%) 30 (90.9%) 152 (95.0%) 38 (90.5%) 0.4756
PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; GFR = glomerular filtration rate; BNP = brain natriuretic peptide; BP = blood pressure; CPK = creatine phosphokinase; 
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; DAPT = dual antiplatelet therapy; BB = beta adrenergic receptor blocker
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was 63.3 ± 12.1 years, and 83.8% of patients were 
male. Blood pressure, shock vitals, decompensated 
heat failure, GRACE risk score on onset and peak 
creatine phosphokinase after primary PCI were not 
significantly different across the three groups. Me-
dications at hospital discharge (including renin-an-
giotensin system inhibitor, statins, and antiplatelet 
therapy) were not significantly different across the 
three groups.
Serial echocardiographic evaluations
Table 2 shows the result of serial echocardiographic 
evaluations. The median interval of serial echocar-
diographic evaluations from acute to chronic pha-
se was 526 days (range: 300 to 1041 days), and 
from STEMI onset to chronic phase echocardiogra-
phic evaluation was 537 days (range: 303 to 1042 
days). The mean LVEFs at the acute and chronic 
Table 2. Serial echocardiographic evaluations.
Overall 
(n=235)
No BB 
(n=33)
Carvedilol 
(n=160)
Bisoprolol 
(n=42)
P value
Acute phase
Days from onset, day 2 (1-11) 1 (1-9.5) 2 (1-13) 2 (1-5.25) 0.3901
LVEF, % 53.9 ± 9.9 58.5 ± 12.5 53.0 ± 9.4 53.6 ± 8.9 0.0134
LA, mm 34.1 ± 7.1 34.5 ± 9.3 33.9 ± 6.6 34.5 ± 7.5 0.8308
LVDd, mm 49.7 ± 6.8 49.3 ± 8.5 49.8 ± 6.6 49.3 ± 5.9 0.8866
LVDs, mm 32.2 ± 6.9 32.3 ± 8.0 32.7 ± 6.9 31.6 ± 6.0 0.5880
IVS, mm 11.0 ± 2.3 10.7 ± 2.2 11.2 ± 2.3 10.5 ± 2.2 0.2505
PW, mm 10.4 ± 1.8 10.4 ± 2.0 10.5 ± 1.7 10.4 ± 1.7 0.9247
EDV, mL 122.5 ± 34.6 115.8 ± 42.2 123.7 ± 33.8 123.3 ± 31.4 0.5211
ESV, mL 45.0 ± 23.0 43.2 ± 25.7 46.2 ± 23.9 42.9 ± 18.1 0.6555
E/A 0.9 ± 0.5 0.9 ± 0.5 0.9 ± 0.5 0.9 ± 0.4 0.8440
DcT, msec 0.21 ± 0.10 0.21 ± 0.05 0.20 ± 0.08 0.23 ± 0.19 0.3123
Late phase
Days from onset, day 537 (303-1042) 414 (212-816) 560 (338.75-1312.5) 456 (282.25-838.5) 0.0031
Interval from 1st 
echocardiography
526 (300-1041) 413 (210.5-813) 541 (334-1282.75) 453 (277.5-814) 0.0034
LVEF, % 56.4 ± 10.6 54.1 ± 12.7 56.6 ± 10.0 57.4 ± 11.3 0.3783
LA, mm 36.4 ± 7.6 37.6 ± 9.7 35.8 ± 6.4 37.7 ± 9.7 0.2120
LVDd, mm 51.2 ± 7.0 50.7 ± 7.2 51.3 ±7.2 51.0 ± 6.3 0.9076
LVDs, mm 33.2 ± 7.8 34.2 ± 8.7 33.0 ± 7.6 33.0 ± 8.0 0.7588
IVS, mm 10.3 ± 2.1 10.3 ± 1.7 10.3 ± 2.1 10.0 ± 2.3 0.5695
PW, mm 9.8 ± 1.5 9.8 ± 1.5 9.8 ± 1.5 9.7 ± 1.3 0.8965
EDV, mL 123.5 ± 39.0 128.1 ± 49.7 122.9 ± 38.0 122.0 ± 33.9 0.7764
ESV, mL 46.7 ± 25.4 46.8 ± 24.2 46.2 ± 25.6 48.2 ± 26.4 0.9130
E/A 0.9 ± 0.5 0.8 ± 0.3 0.8 ± 0.3 1.1 ± 1.0 0.0299
DcT, msec 0.23 ± 0.06 0.21 ± 0.04 0.23 ± 0.07 0.21 ± 0.04 0.1017
LVEF = left ventricular ejection fraction; LA = left atrium; LVDd = left ventricular diastolic diameter; LVDs = left ventricular systolic diameter; 
IVS = interventriclr septum; PW = posterior wall; EDV = end-diastolic volume; ESV = end-systolic volume; 
E/A = early diastolic filling velocity/ atrial filling velocity; DcT = decelaration time; BB = beta adrenergic receptor blocker
InternatIonal archIves of MedIcIne 
sectIon: cardIology 
ISSN: 1755-7682
2016
Vol. 9 No. 115
doi: 10.3823/1986
© Under License of Creative Commons Attribution 3.0 License 7
phases in the overall population were 53.9 ± 9.9% 
and 56.4 ± 10.6%, respectively. In the evaluation 
during the acute phase, the no BB group had a sig-
nificantly lower LVEF than the BB group (carvedilol 
and bisoprolol groups combined) (P=0.0134). The 
changes in end-systolic volume (ESV), end-diastolic 
volume (EDV), and LVEF are shown in Figure 2. The 
ESV showed no significant differences regardless of 
BB therapy or no BB therapy (P=0.3422), and EDV 
in no BB group showed a significant increase at 
the chronic phase evaluation than seen in the BB 
therapy group (P=0.0171). The LVEF decreased at 
chronic phase evaluation point in the no BB group; 
on the other hand, the BB therapy groups showed 
LVEF improvement (-4% [range: -8 to -1%] vs. +2% 
[range: 0 to 7.3%], P<0.0001). In comparison across 
the three groups, no BB vs. carvedilol vs. bisoprolol, 
both the carvedilol and bisoprolol groups showed 
LVEF improvement (-4% [range: -8 to -1%] vs. +2% 
[range: 0 to 8%] vs. +4% [range: 0 to 7%], respec-
tively; P<0.0001).
Dose-dependence of BB efficacy for LVEF 
improvement
To study the relationship between dosage of BB and 
the magnitude of LVEF improvement, LVEF improve-
ment was analyzed by dividing into subgroup accor-
ding to BB dose (Figure 3). The no BB and carvedilol 
groups were divided into three subgroups: minimum 
dose: <5 mg (n=65), medium dose: ≥5 mg and <10 
mg (n=64), and regular dose: ≥10 mg (n=64). The 
minimum dose of carvedilol did not have sufficient 
effect to improve LVEF, however the magnitude of 
LVEF improvement with carvedilol increased dose-
Figure 2:  Comparisons of ESV, EDV, and LVEF 
transitions between no BB and BB 
treatment.
Changes in ESV, EDV, and LVEF from acute to chronic phase are demonstrated 
by BB therapy. The EDV with no BB therapy was significantly greater than 
seen with BB therapy; however, there was no significant difference in ESV. 
The LVEF decreased in the no BB group, but improvement was shown in the 
BB group, carvedilol, and bisoprolol group.
Figure 3:  Dose-dependence of BB to LVEF impro-
vement.
The changes in LVEF were demonstrated in the carvedilol (left panel) and 
bisoprolol (right panel) groups, which was classified according to BB dosage 
at hospital discharge. The carvedilol group was divided three subgroups: 
minimum dose (<5 mg), medium dose (≥5 mg and <10 mg), and regular dose 
(≥10 mg). The LVEF decreased -2% from that of baseline with the minimum 
dose. In contrast, the medium dose demonstrated +2% improvement with a 
significant difference compared to the minimum dose. Moreover, the regular 
dose demonstrated a significantly better +6.5% improvement than seen 
with the medium dose. The RR achievement rate was 1.5% (1/65), 14.1% 
(9/64), and 32.8% (21/64), respectively (P<0.0001). The bisoprolol group 
was divided into two subgroups: minimum dose (<1.25 mg) and regular 
dose (≥1.25 mg). The minimum dose didn’t produce LVEF improvement, but 
the regular dose did (-2% vs. +4%, P<0.0001). In these patients, the RR 
achievement rate was 0% (0/42) and 21.2% (7/44), respectively (P=0.0022).
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dependently (-2% with minimum dose [range: -6 
to 0%] vs. +2% with medium dose [range: 0 to 
4%] vs. +6.5% with regular dose [range: 2 to 12%], 
P<0.0001; left panel, Figure 3). The RR achievement 
rate among these subgroups also showed dose-de-
pendent increases of 1.5% (1/65), 14.1% (9/64), and 
32.8% (21/64), respectively (P<0.0001).
The no BB and bisoprolol groups were divided into 
two subgroups: minimum dose: <1.25 mg (n=42) 
and regular dose: ≥1.25 mg (n=33). As seen with 
carvedilol, minimum dose bisoprolol didn’t demons-
trated LVEF improvement, and the regular dose did 
lead to LVEF improvement (-2% [range: -7 to 0.5%] 
vs. +4% [range: 0 to 8.5%], P<0.0001; right panel, 
Figure 3). The RR achievement rate was 0% (0/42) 
and 21.2% (7/44), respectively (P=0.0022).
Multivariate analysis for predictors of left 
ventricular reverse remodeling
RR was shown in 16.2% of the overall population. 
BB therapy with carvedilol and bisoprolol showed 
a significantly higher RR achievement rate than did 
the no BB group (no BB group 0%, carvedilol group 
19.4%, bisoprolol group 16.7%, P=0.0225).
To identify the clinical predictors of RR, the fo-
llowing variables were examined by multivariate lo-
gistic analysis: age, male gender, diabetes mellitus, 
estimated GFR, LVEF <50% at acute phase, angio-
tensin-converting enzyme inhibitor use (compared 
to angiotensin II receptor blockers), statin use, and 
regular dose of BB (≥10 mg of carvedilol or ≥1.25 
mg of bisoprolol) (Table 3). Both LVEF <50% at 
acute phase and regular dose of BB were found 
to be independent predictors of RR (LVEF <50% 
at acute phase: Odds ratio 2.35, 95% CI 1.12-5.02, 
P=0.0242; regular dose of BB: Odds ratio 4.45, 95% 
CI 2.06- 10.27, P=0.0001).
To confirm the above results of multivariate 
analysis, the three groups were further divided into 
subgroups according to LVEF <50% and regular 
dose of BB: baseline LVEF <50% and receiving ≥10 
mg of carvedilol (n=34) or not (n=159), or ≥1.25 
mg of bisoprolol (n=15) or not (n=60) (Figure 4). In 
Table 3. Multivariable analysis for predictors of left 
ventricular reverse remodeling.
Variables
Univariate Multivariate
P value 
(95% CI)
Odds ratio 
(95% CI)
P 
value
Age 0.5213 
(0.98 - 1.03)
Male
0.1526 
(0.13 - 1.28)
Diabetes mellitus
0.1193 
(0.28 - 1.16)
Estimated GFR
0.2975 
(0.99 - 1.02)
Baseline LVEF 
<50%
0.0020 
(1.50 - 6.33)
2.35 
(1.12 - 5.02)
0.0242
Favor ACEI over 
ARB
0.2498 
(0.71 - 3.43)
Statin
0.1121 
(0.82 - 5.63)
Regular dose of 
BB‡
<0.0001 
(2.45 - 11.83)
4.45 
(2.06 - 10.27)
0.0001
GFR = Glomerular filtration rate; LVEF = left ventricular ejection 
fraction; ACEI = angiotensin converting enzyme inhibitor; ARB = 
angiotensin II receptor blocker; BB = beta-adrenergic blockers. 
‡: ≥10 mg of carvedilol or ≥1.25 mg of bisoprolol IVS = interventriclr 
septum; PW = posterior wall; 
EDV = end - diastolic volume; ESV = end - systolic volume; 
E/A = early diastolic filling velocity/ atrial filling velocity; 
DcT = decelaration time; BB = beta adrenergic receptor blocker
Figure 4:  Impact of regular dose of BB in LVEF 
<50%.
The impact of the regular dose of BB, which is ≥10 mg of carvedilol or ≥1.25 
mg of bisoprolol, on the magnitude of LVEF improvement in patients where 
the LVEF <50% was assessed.
In the carvedilol group, patients with an LVEF <50% treated with regular 
dose (n=34) had +8% (range: 2 to 13.25%), and another (n=159) had +1% 
(range: -7 to 4%) change in LVEF (P<0.0001). The RR achievement rates for 
these patients were 44.1% and 10.1% (P=0.0006), respectively.
In the bisoprolol group, the change in LVEF was +4% (range: 0 to 7%) and 
-1% (range: -5.75 to 4%), respectively (P=0.0903). The RR achievement rates 
were 13.3% (2/15) and 8.3% (5/60), respectively (P=0.6217).
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the carvedilol group, the change in LVEF in the “EF 
<50% and >10 mg group” compared with the “EF 
≥50% or <10 mg group” was +8% (range: 2 to 
13.25%), and another was +1% (range: -7 to 4%) 
(P<0.0001). The RR achievement rates were 44.1% 
(15/34) and 10.1% (16/159), respectively (P=0.0006). 
In the bisoprolol group, the same tendency was de-
monstrated, although there was no significant diffe-
rence: +4% (range: 0 to 7%) vs. -1% (range: -5.75 
to 4%), P=0.0903. The RR achievement rate was 
13.3% (2/15; the EF <50% and > 1.25 mg group) 
and 8.3% (5/60; the EF >50% or <1.25 mg group), 
respectively (P=0.6217).
Discussion
This study revealed the relationship between BB 
dose and the magnitude of LVEF improvement in 
STEMI following primary PCI using serial echocar-
diography assessment. Early BB introduction was re-
lated to improvement of LVEF and dose-dependent 
RR achievement. Baseline LVEF <50% and regular 
dose of BB administration were suggested as inde-
pendent predictors of RR achievement.
It is well-established that BB has efficacy in im-
proving LVEF and long-term outcomes in chronic 
heart failure. [16-22] On the other hand, the impact 
of BB therapy on STEMI immediately after successful 
primary PCI may be discussed separately from that 
of chronic heart failure. In the 2013 American Co-
llege of Cardiology Foundation/American Heart As-
sociation guidelines for treatment of patients with 
STEMI, BB therapy is recommended for all STEMI 
patients who do not have signs of heart failure, low 
output state, increased risk for cardiogenic shock, 
or other contraindications defined as Class I. [10] In 
the 2012 European Society of Cardiology guidelines 
for treatment of patients with STEMI, BB therapy is 
recommended for STEMI patients with heart failure 
or left ventricular dysfunction defined as Class IA, 
and for all STEMI patients without contraindications 
defined as Class IIa. [23] However, most of these 
recommendations were based on data obtained 
before the primary PCI era. [24-32] Recently, some 
trials have raised an important question regarding 
BB therapy for STEMI patients. The OACIS trial de-
monstrated that BB was not always beneficial for 
all STEMI patients, since low-risk patients defined 
according to the GRACE risk score did not have 
clinical benefits. [11] Post-hoc sub-analysis of the 
J-Cypher registry showed BB therapy produced no 
significant difference in 3-year mortality or in in-
cidence of major adverse cardiac events in STEMI 
patients with primary PCI, and only patients with 
LVEF ≤40% showed improvement in these outco-
mes. [9] Moreover, sub-analysis of the VALIANT 
trial demonstrated the additional benefit of BB on 
renin-angiotensin system inhibitors was unclear in 
acute myocardial infarction. [33] In the REACH re-
gistry, which analyzed over 44,000 patients with 
prior myocardial infarction, BB therapy did not show 
superiority in primary outcome of cardiovascular 
death, nonfatal MI, or nonfatal stroke, even after 
propensity score-matched adjustment. [34] A meta-
analysis published in 2015 showed that depressed 
LVEF, non-STEMI, and undertreated therapies were 
suggested as a beneficial subgroup with BB in acute 
myocardial infarction. [35] 
The present study demonstrated that ESV did not 
change between acute and chronic phases, but EDV 
decreased significantly. This finding suggests that 
the effect of BB was prevention of left ventricular di-
lation, rather than improvement of systolic function. 
The CAPRICORN Echo Substudy demonstrated +5% 
improvement of LVEF with carvedilol at 6 months 
after acute myocardial infarction. [36]　Although 
CAPRICORN did not analyze the dosage of carve-
dilol, the efficacy is considered as equivalent to our 
results. As with the above suggestions from the 
OACIS trial and J-Cypher registry, decreased LVEF 
patients were evaluated as a subgroup sensitive for 
BB efficacy. [9, 11]
The necessary BB dosage to improve LVEF 
or achieve RR has not been discussed enough, 
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because the major focus in prior studies was 
whether administration of BBs was better than 
no administration. Since it is quite unlikely that a 
minimum dose of BB could improve enough LVEF 
or RR significantly, the next problem in clinical 
implications is how much we should increase the 
dosage when the patients are discharged from 
the hospital. [37-39] Our study suggests that a 
minimum dose of BB was not sufficient to achieve 
RR. Thus, it may be necessary to increase up to 
regular dose at hospital discharge in STEMI pa-
tients following primary PCI. [40-46] Prospective 
investigation is required to confirm our sugges-
tion, BB administration during 6 months impro-
ve LVEF dose-dependently among <5mg, ≥5 to 
<10mg, and ≥10mg of carvedilol, and between 
<1.25mg and ≥1.25mg of bisoprolol.
There are several limitations in our study. First, 
this was a retrospective study. Second, the study 
may have been underpowered to draw a conclu-
sion on efficacy of BB therapy on LVEF improve-
ment. Third, the duration of BB therapy did not 
include the present discussion, since the duration 
of BB therapy and interval of echocardiographic 
evaluation differed between individuals studied. 
Fourth, other medications, excluding BB and renin-
angiotensin system inhibitor, were not included the 
present discussion. Fifth, patient compliance with 
medication is less clear. Present study did not as-
sess the impact of BB initiation timing on LVEF 
improvement although Bugiardini et al reported 
earlier administration of oral BB therapy with a 
greater probability of improving LV function and 
in-hospital survival rate. [47]
In conclusion, immediate BB administration after 
STEMI onset following primary PCI provides a dose-
dependent LVEF improvement. For patients with de-
creased LVEF <50%, administration of the regular 
dose of BB might be reasonable to achieve RR.
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